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Abstract
Background: Obstructive Sleep Apnea (OSA) is tightly linked to some components of Metabolic Syndrome (MetS). However,
most of the evidence evaluated individual components of the MetS or patients with a diagnosis of OSA that were referred
for sleep studies due to sleep complaints. Therefore, it is not clear whether OSA exacerbates the metabolic abnormalities in
a representative sample of patients with MetS.
Methodology/Principal Findings: We studied 152 consecutive patients (age 4869 years, body mass index 32.363.4 Kg/m
2)
newly diagnosed with MetS (Adult Treatment Panel III). All participants underwent standard polysomnography irrespective
of sleep complaints, and laboratory measurements (glucose, lipid profile, uric acid and C-reactive protein). The prevalence of
OSA (apnea-hypopnea index $15 events per hour of sleep) was 60.5%. Patients with OSA exhibited significantly higher
levels of blood pressure, glucose, triglycerides, cholesterol, LDL, cholesterol/HDL ratio, triglycerides/HDL ratio, uric acid and
C-reactive protein than patients without OSA. OSA was independently associated with 2 MetS criteria: triglycerides: OR: 3.26
(1.47–7.21) and glucose: OR: 2.31 (1.12–4.80). OSA was also independently associated with increased cholesterol/HDL ratio:
OR: 2.38 (1.08–5.24), uric acid: OR: 4.19 (1.70–10.35) and C-reactive protein: OR: 6.10 (2.64–14.11). Indices of sleep apnea
severity, apnea-hypopnea index and minimum oxygen saturation, were independently associated with increased levels of
triglycerides, glucose as well as cholesterol/HDL ratio, uric acid and C-reactive protein. Excessive daytime sleepiness had no
effect on the metabolic and inflammatory parameters.
Conclusions/Significance: Unrecognized OSA is common in consecutive patients with MetS. OSA may contribute to
metabolic dysregulation and systemic inflammation in patients with MetS, regardless of symptoms of daytime sleepiness.
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Introduction
Metabolic syndrome (MetS) constitutes a clustering of metabolic
and cardiovascular abnormalities including central obesity, insulin
resistance, dyslipidemia, and increased blood pressure in the same
individual [1]. Despite some controversy, MetS is associated with
higher cardiovascular risk than one might expect from simple
addition of its individual components [2–4]. However, other
factors may contribute to the high cardiovascular burden observed
in patients with MetS.
Obstructive sleep apnea (OSA) is characterized by recurrent
episodes of partial or complete obstruction of the upper airway,
intermittent hypoxia and frequent arousals from sleep [5].
There is abundant evidence from humans and animals
suggesting that OSA may impact every aspect of MetS,
including obesity [6], hypertension [7], insulin resistance [8]
and dyslipidemia [9,10]. Furthermore, OSA and MetS have
been previously shown to co-exist [11–20]. However, previous
studies were limited by small sample size and/or selection bias,
because they included patients referred for sleep studies due to
sleep-related complaints. Thus ,t h ep r e v a l e n c ea n di m p a c to f
OSA in consecutive patients with MetS have not been
adequately explored. It is not certain whether the overlap
between OSA and MetS is simply a result of underlying obesity,
or if OSA represents an additional burden that exacerbates
metabolic dysfunction and systemic inflammation in patients
with MetS. The impact of daytime sleepiness on markers of
cardiovascular risk in patients with MetS is unknown.
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12065In the present investigation we enrolled consecutive patients
with MetS with no previous diagnosis of OSA in order to evaluate
if the presence of OSA is independently associated with (1)
parameters of MetS, (2) parameters associated with cardiovascular
risk but not included in the MetS definition. Moreover, we
explored if effects of OSA on metabolic and inflammatory indices
are modulated by the extent of daytime sleepiness.
Materials and Methods
Ethics Statement
The local Ethics Committee (Institutional Review Board –
Heart Institute) approved the protocol, and all participants gave
written informed consent.
Patients
We studied consecutive patients with a recent diagnosis of MetS
recruited from the Heart Institute (InCor) from October 2008 to
December 2009. All participants were asymptomatic outpatients
admitted for routine check-up evaluations. No sleep questionnaire
was applied at the time of the recruitment. Patients with established
cerebrovascular disease, coronary disease, heart failure, rheumato-
logic diseases, renal failure; hypothyroidism, pregnancy, history of
smoking, and regular exercisers were excluded as well as patients
with a previous diagnosis of OSA. In addition, we excluded patients
who were using hypoglycemic medications, insulin, fibrates, statins,
uricosuric agents (such as allopurinol), steroids and contraceptives.
All participants underwent a detailed history and physical. The
body mass index was calculated after body weight and height were
measured in subjects wearing light clothing without shoes. Waist
circumference was measured with soft tape on standing subjects
midway between the lowest rib and the iliac crest. Two blood
pressure recordings were obtained from the right arm of patients in
a sitting position after 15 minutes of rest at 5-minute intervals, and
their mean value was calculated. The diagnosis of hypertension was
based on current guidelines [21].
Blood samples
Fasting blood samples were drawn for determination of glucose,
total cholesterol, low-density lipoprotein (LDL), high-density
lipoprotein (HDL), triglycerides, and uric acid using enzymatic
methods. High-sensitivity C-reactive protein was measured by
using particle enhanced immunonephelometry (Dade Behring,
Inc. Deerfield, Illinois). All samples were collected in the absence
of clinical evidence of active infection/ inflammatory processes
such as viral infections.
Definition of metabolic syndrome
MetS was diagnosed according to the National Cholesterol
Education Program, Adult Treatment Panel III (NCEP III) (1), if
3 of the 5 following factors were present: 1) waist circumference
($102 cm in men and $88 in women), 2) triglycerides $150 mg/
dL, or patient on specific drug treatment, 3) HDL ,40 mg/dL in
men and ,50 mg/mg/dL in women, or when on specific drug
treatment, 4) arterial blood pressure $130 or 85 mm Hg for
systolic and diastolic blood pressure, respectively, or patient on
antihypertensive drug treatment, and 5) fasting glucose $100 mg/
dL or patient on specific drug treatment.
Sleep Parameters
Within 1 month after blood sample collection, all participants
underwent a standard overnight polysomnography as previously
described [22]. Apnea was defined as complete cessation of airflow
for at least 10 seconds, associated with oxygen desaturation of 3%.
Hypopnea was defined as a reduction in respiratory signals for at
least 10 seconds associated with oxygen desaturation of 3%. The
apnea-hypopnea index (AHI) was calculated as the total number of
respiratory events (apneas plus hypopneas) per hour of sleep. The
AHI cutoffs for mild, moderate and severe OSA were 5 to 14.9, 15
to 29.9, and $30 events per hour of sleep, respectively. Because of
a high expected prevalence of OSA in this population, the
presence of OSA was also restricted to the moderate to severe
cases, i.e., AHI $15 events per hour of sleep as previously
described [18]. Daytime somnolence was evaluated by the
Epworth sleepiness scale [23], with a score of .10 considered
excessive daytime sleepiness.
Statistical Analysis
Data were analyzed with SPSS statistical software version 18.0
(Chicago, Illinois, USA). The comparison of continuous variables
between patients with and without OSA was performed using the
Student t test or Mann-Whitney test, when appropriate.
Categorical variables were expressed by frequency distribution
and were compared using the Fisher exact test. Continuous
variables with normal distribution were expressed as mean 6SD.
Otherwise, they were presented as median (interquartile range). In
order to analyze the relative role of OSA either as a categorical
variable (presence or absence of OSA) or as a continuous one
(AHI, minimum oxygen saturation during sleep and total sleep
time below 90%) we performed two independent analyses: 1)
Univariable and multivariable logistic regression analysis to model
the association of each MetS criteria (waist circumference,
triglycerides, HDL, blood pressure and glucose) and non-MetS
risk factors (cholesterol/HDL ratio $4.5 [24], triglycerides/HDL
ratio .3 [25], C-reactive protein .3 mg/L [26] and uric acid
.7 mg/dL [27]) according to the presence of OSA (adjusted for
age, sex, race, body mass index and waist circumference); 2)
Multiple linear regression analysis (Stepwise linear regression
analysis) to evaluate the relative role of markers of OSA severity
with absolute values of components of MetS and metabolic and
inflammatory variables not included in the MetS criteria
(cholesterol/HDL ratio, uric acid and C-reactive protein). We
used a P=0.15 as the critical value for entering/excluding
variables in the model. Independent variables were age, sex, race,
body mass index, waist circumference and sleep parameters. In all
multiple regression analysis we avoided the presence of multi-
collinearity. In a subgroup of patients with MetS and OSA, we
also performed a comparison of the independent variables
associated with the presence of OSA according to the presence
or absence of excessive daytime sleepiness.
Results
We initially enrolled 210 consecutive patients with a recently
confirmed diagnosis of MetS. The final sample was comprised of
152 patients, because 58 subjects met one or more exclusion criteria
(Figure 1). Characteristics of patients including age, sex, body mass
index and waist circumference were not different between patients
included and excluded from the study (P.0.2 for all comparisons).
Forty participants (26.3%) were involved in the previous study
evaluating the impact of OSA on markers of atherosclerosis in
consecutive patients with MetS [28]. Notably only 7 (3.3%) were
excluded from the initial screening because of a previous diagnosis
ofOSA.TheprevalenceofOSA(AHI $15eventsperhourofsleep)
in patients with MetS was 60.5%.
Twenty seven patients (17.8%) presented with an AHI ,5
events per hour of sleep. Thirty three patients (21.7%) presented
with an AHI from 5 to 14.9 events per hour of sleep. Moderate
OSA in Metabolic Syndrome
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(AHI $30 events per hour of sleep) were observed in 34 (22.4%)
and 58 patients (38.1%), respectively. The demographic, anthro-
pometric and sleep characteristics of the total population of
patients studied, as well as comparisons of patients with or without
OSA are shown in Table 1. Overall, the present sample included
middle age patients. As expected, the great majority of participants
were obese with high waist circumference measurements. There
were no significant differences in sex, race, body mass index, waist
circumference, hypertension, and diabetes status between patients
with and without OSA. The anti-hypertensive medications were
also similar between hypertensive patients with and without OSA:
diuretics (75% vs. 72%), beta-blockers (38% vs.55%), calcium
channel blockers (44% vs. 34%), angiotensin-converting enzyme
inhibitors (64% vs. 50%) and angiotensin II receptor blockers
(22% vs. 17%), were similar (P.0.1 for all comparisons). MetS
patients with OSA were older (Table 1). Patients with OSA met a
higher number of MetS criteria due to the higher rate of
hypertriglyceridemia and hyperglycemia than patients without
OSA (Figure 2 and 3). Patients with OSA and MetS had
significantly higher levels of MetS-defining parameters including
blood pressure, fasting blood glucose and serum triglycerides
compared to patients with MetS alone (Table 2). The levels of
HDL were similar between patients with and without OSA. In
contrast, the levels of several non-MetS parameters including
serum total cholesterol, LDL, triglycerides/HDL ratio, cholester-
ol/HDL ratio, uric acid and C-reactive protein were also higher in
patients with OSA.
Univariableandmultivariablelogisticregression analysis (Table3)
showed that the presence of OSA was independently associated with
2 of 5 criteria for MetS (triglycerides and glucose). Moreover, the
presence of OSA was independently associated with abnormally
elevated cholesterol/HDL ratio, uric acid and C-reactive protein.
There wasastrongtrend foran independentassociation between the
presence of OSA and triglycerides/HDL ratio.
Multiple linear regression analysis showed that the AHI or
minimum oxygen saturation during sleep were independently
associated with serum levels of triglycerides and glucose as well as
with several metabolic and inflammatory parameters not included
in the MetS criteria (cholesterol/HDL ratio, uric acid and C-
reactive protein - Table 4). Although C-reactive protein has a
skewed distribution, the residuals from this model were normally
distributed.
Systolic and diastolic blood pressure were independently related
only to age (data not shown; P,0.001 for both comparisons).
Figure 4 shows that the independent variables associated with
OSA (glucose, triglycerides, cholesterol/HDL ratio, uric acid and
C-reactive protein) were similar in patients with and without
excessive daytime sleepiness.
Figure 1. Patient flow diagram. Some patients had multiple
exclusions reasons. OSA: Obstructive Sleep Apnea. PSG: Polisomno-
graphy.
doi:10.1371/journal.pone.0012065.g001
Table 1. Patient characteristics.
Total Sample (n=152) No OSA (n=60) OSA (n=92) P value*
Age (years) 48694 6 684 9 68 0.02
Males (%) 62.5 55 67 0.13
Caucasians (%) 74 70 77 0.34
Body mass index (kg/m
2) 32.363.4 32.263.8 32.363.2 0.76
Hypertension (%) 66.4 61.7 69.6 0.38
Diabetes (%) 7.9 9.1 8.2 1.00
Number of MetS criteria (n) 3( 3 24) 3 (324) 4 (324) ,0.01
Apnea-hypopnea index (events/hour) 19.6 (7.1239.0) 5.0 (2.628.8) 34.7 (25.0254.3) ,0.001
Lowest oxygen saturation (%) 83 (74287) 87 (85290) 77 (69284) ,0.001
Total sleep time oxygen saturation ,90% (%) 3.0 (0.2210.0) 0.3 (021.8) 8.9 (2.7224.5) ,0.001
Epworth sleepiness scale 10 (8211) 9 (8210) 10 (8212) 0.03
Excessive daytime sleepiness,{ n( % ) 47 (30.9) 14 (23.3) 33 (35.9) 0.11
*For comparisons between MetS patients with and without OSA. {Epworth sleepiness scale score .10.
MetS: Metabolic Syndrome. OSA: Obstructive Sleep Apnea. Variables with normal distribution are expressed as mean6SD. Variables with skewed distribution are
presented as median (interquartile range).
doi:10.1371/journal.pone.0012065.t001
OSA in Metabolic Syndrome
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The present study showed that, in consecutive patients with
MetS, unrecognized OSA is common and independently associ-
ated with biomarkers of metabolic dysfunction and systemic
inflammation. Specifically, OSA was associated with two MetS
criteria, triglycerides and glucose; and with three non-MetS
cardiovascular risk factors, cholesterol/HDL ratio, uric acid, and
C-reactive protein. These associations were not influenced by the
presence or absence of excessive daytime sleepiness. Taken
together, our data suggest that OSA may contribute to the
metabolic and cardiovascular burden of patients with MetS.
Previous clinical studies of MetS failed to consider OSA as a
potential confounding factor that contributes the cardiovascular
risk [29,30]. Accordingly, the American Heart Association
Scientific statement on MetS briefly discussed OSA and classified
it as being of interest to ‘‘other fields of medicine,’’ giving it the
same attention given to cholesterol gallstones and lypodystrophies
[1]. Conversely, the majority of previous investigations derived
from the sleep community were intrinsically biased studying only
patients referred for sleep studies [11–16]. Our study design
allowed us to systematically examine the prevalence of unrecog-
nized OSA in consecutive sample of patients with MetS. We found
a 60.5% prevalence of OSA in MetS, even using conservative
Figure 2. Rate of MetS criteria in patients with and without OSA.
doi:10.1371/journal.pone.0012065.g002
Figure 3. Frequency of each MetS criteria between groups (B).
doi:10.1371/journal.pone.0012065.g003
OSA in Metabolic Syndrome
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prevalence of OSA observed in this study is in line with two
previous reports from different groups (ranging from 68 to 87.5%)
that evaluated patients with MetS [17,18]. Consistently with our
data, a recent report found a high prevalence of OSA (,86%) in
obese patients with type 2 diabetes [31]. The high prevalence of
OSA among our consecutive patients with MetS may be due to the
shared feature of visceral obesity in both syndromes. In fact,
visceral rather than the subcutaneous or total body fat predisposes
to the development of OSA [32]. However, the effect of OSA on
metabolic function in MetS, at least in terms of glucose control,
has been shown to occur independently of waist circumference, a
surrogate marker of visceral adiposity [18]. In the present larger
study, which excluded patients treated with hypoglycemic and
lipid-lowering medications, we show that the co-existence of OSA
in patients with MetS is associated with increased glucose and
triglycerides levels.
We have also shown that OSA is associated with non-MetS
cardiovascular risk markers, including cholesterol/HDL ratio, uric
acid, and C-reactive protein. These biomarkers have validated as
indices of the cardiovascular risk. A large prospective study
showed that a cholesterol/HDL ratio .4.5 is a better predictor of
ischemic heart disease than total cholesterol, HDL cholesterol, or
non-HDL cholesterol [33]. Uric acid, the catabolic end product of
ATP, is associated with oxidative stress, inflammation, subclinical
atherosclerosis, and an increased risk of cardiovascular events [34–
36]. Independent studies have shown that plasma uric acid is often
elevated in subjects with the MetS and OSA [37,38]. Our study
suggests that OSA has an additive effect on uric acid levels in
patients with MetS. Finally, pro-inflammatory effects of MetS and
Table 3. Univariable and multivariable logistic regression analysis for the association between presence of OSA with variables
included and not included in the MetS criteria.
Unadjusted odds ratio (95% CI) Adjusted odds ratio (95% CI)* Adjusted P value
Variables included in MetS criteria
Waist circumference criteria 0.75 (0.2422.30) 0.73 (0.2122.50) 0.61
Triglycerides criteria 2.94 (1.4326.02) 3.26 (1.4727.21) 0.004
HDL-C criteria 0.91 (0.4621.83) 0.87 (0.4221.80) 0.71
Arterial blood pressure criteria 1.20 (0.5622.58) 1.02 (0.4522.32) 0.96
Fasting glucose criteria 2.54 (1.2925.01) 2.31 (1.1224.80) 0.02
Variables not included in MetS criteria
Total cholesterol/HDL ratio $4.5 2.40 (1.1724.91) 2.38 (1.0825.24) 0.03
Triglycerides/HDL ratio .3 2.21 (1.0424.68) 2.19 (0.9525.04) 0.07
Uric Acid .7 mg/Dl 4.18 (1.7829.82) 4.19 (1.70210.35) 0.002
C-reactive protein .3 mg/L 4.92 (2.41210.03) 6.10 (2.64214.11) ,0.001
*Adjusted for age, sex, race, body mass index and waist circumference (except for waist circumference criteria).
doi:10.1371/journal.pone.0012065.t003
Table 2. Quantitative values of metabolic and inflammatory profile in Metabolic Syndrome patients with and without Obstructive
Sleep Apnea.
Total Sample (n=152) No-OSA (n=60) OSA (n=92) P value*
Variables included in MetS criteria
Waist circumference (cm) 105.168.2 10469 10668 0.16
Triglycerides (mg/dL) 196686 170681 213685 0.002
HDL cholesterol (mg/Dl) 39 (34247) 39 (33247) 38 (34247) 0.83
Systolic blood pressure (mm Hg) 139624 134622 142624 0.03
Diastolic blood pressure (mm Hg) 84614 81614 86615 0.05
Fasting glucose (mg/dL) 102611 98610 105611 ,0.001
Variables not included in MetS criteria
Total cholesterol (mg/dL) 216639 204632 223636 0.003
Total cholesterol/HDL ratio 5.561.4 5.161.4 5.761.5 0.02
Triglycerides/HDL ratio 5.162.9 4.462.5 5.662.9 0.009
Uric acid (mg/dL) 6.561.4 5.861.3 6.961.4 ,0.001
C-reactive protein (mg/dL) 3.0 (2.024.0) 2.6 (1.323.2) 3.9 (2.724.4) ,0.001
*For comparisons between patients with and without OSA.
doi:10.1371/journal.pone.0012065.t002
OSA in Metabolic Syndrome
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independent studies reported that both MetS [26] and OSA [39]
are independently associated with high C-reactive protein levels,
which is a marker of cardiovascular inflammation. C-reactive
protein adds clinically important prognostic information to the
MetS [26]. Collectively, our study suggests that the severity of OSA
Table 4. Stepwise linear regression analysis for the association between markers of OSA severity and components of MetS and
metabolic/inflammatory variables not included in the MetS criteria*.
Variables Coefficient (b) 95% CI P value
Variables included in MetS criteria
Triglycerides Race 214.530 227.930 21.150 0.03
Body mass index 25.670 210.740 20.600 0.03
Minimum O2 saturation 22.079 24.12020.040 0.04
Glucose Age 0.315 0.108 0.522 0.003
Apnea-hypopnea index 0.081 0.014 0.148 0.02
Variables not included in MetS criteria
Cholesterol/HDL ratio Apnea-hypopnea index 0.013 0.004 0.022 0.006
Uric Acid Sex 0.845 0.349 1.342 0.001
Apnea-hypopnea index 0.013 0.002 0.024 0.02
C-reactive protein Minimum O2 saturation 20.042 20.07220.013 0.005
Sex 20.632 21.24920.002 0.04
Age 0.036 0.003 0.070 0.03
*Variables used in the model: age, sex, race, body mass index, waist circumference and sleep parameters (apnea-hypopnea index, minimum O2 saturation during sleep
and total sleep time below 90%).
doi:10.1371/journal.pone.0012065.t004
Figure 4. Levels of glucose, triglycerides, cholesterol/HDL ratio, uric acid and C-reactive protein in patients with MetS and OSA
according to the presence or absence of excessive daytime sleepiness.
doi:10.1371/journal.pone.0012065.g004
OSA in Metabolic Syndrome
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uricemia and inflammation in consecutive patients with MetS.
The independent association of OSA with dyslipidemia and
systemic inflammation observed in our study has biological basis.
Intermittent hypoxia, the hallmark of OSA, causes dyslipidemia in
mice by up-regulating hepatic lipid biosynthesis and lipoprotein
secretion via hypoxia inducible factor 1 alpha [9,10]. Intermittent
hypoxia also activates pro-inflammatory transcription factors such
as nuclear factor kappa B that promote activation of various
inflammatory cells with the downstream consequence of expres-
sion of pro-inflammatory mediators that may lead to endothelial
dysfunction [40].
In the present study, we found that several metabolic and
inflammatory markers associated with OSA were similar in
patients with and without excessive daytime sleepiness. Other
investigators have also shown that OSA is associated with markers
of atherosclerosis [28] and mortality irrespective of daytime
symptoms [41]. These collective results challenge the notion that
only sleepy patients with OSA are at increased cardiovascular risk.
OSA may not be suspected in non-sleepy persons, and, therefore,
overlooked as a potential cardiovascular risk factor.
The main strength of our study is the study design, since
consecutive subjects with MetS underwent full polysomnography,
regardless of their sleep complaints. The main limitations are:
First, the present study comprised a relatively small number of
participants. The observation of a nonsignificant trend of an
independent association between OSA and triglicerydes/HDL
ratio, a marker of insulin resistance, may be due to the lack of
power to detect this difference. Therefore, the impact of OSA in
patients with MetS may be even greater. Second, our patients
were middle-aged and without a history of coronary disease and
stroke or intake of statins, fibrates and hypoglycemic drugs. Hence,
our results may not be applicable to other age groups, or patients
with established cardiovascular disease. On the contrary, the
exclusion of drugs that directly affect the metabolic and
inflammatory profile in MetS may be an advantage for studying
metabolic and pro-inflammatory effects of OSA. Third, we were
unable to exclude patients on anti-hypertensive treatment, since
more than 50% of patients were on medications, which could not
be discontinued for ethical reasons. Finally, the cross sectional
nature of the study does not prove cause-effect relationships
between OSA and metabolic and inflammatory markers.
In conclusion, we have shown that OSA is highly common in
patients with MetS. OSA is independently associated with
increased prevalence and severity of hypertriglyceridemia and
hyperglycemia, as well as with several other markers of metabolic
and inflammatory dysregulation (cholesterol/HDL ratio, uric acid
and C-reactive protein). Our data strongly suggest that patients
with MetS need to be evaluated for OSA regardless of daytime
sleepiness. We hypothesize that the presence of OSA can
exacerbate MetS and further increase cardiovascular morbidity
and mortality. Future interventional studies will demonstrate
whether treatment of OSA will improve MetS and cardiovascular
outcomes in these patients.
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